HIGHLIGHTS
- who: James R. Cockey from the Razi University, Iran have published the research: Racing CARs to veterinary immuno-oncology, in the Journal: (JOURNAL)
SUMMARY
One of the first human ACTs used isolated tumor infiltrating lymphocytes (TILs) and selected for cells with a T_cell receptor (TCR) specific toward a tumor neoantigen presented on MHC I of the tumor. Although promising, a significant advance in ACT that takes advantage of the specificity and affinity of antibodies against a tumor surface antigen, rather than relying on endogenous T_cell receptors (TCRs), is chimeric antigen receptors (CARs). Retrospective . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.